Mitochondrial Bol1 and Bol3 function as assembly factors for specific iron-sulfur proteins

  1. Marta A Uzarska
  2. Veronica Nasta
  3. Benjamin D Weiler
  4. Farah Spantgar
  5. Simone Ciofi-Baffoni
  6. Maria Rosaria Saviello
  7. Leonardo Gonnelli
  8. Ulrich Mühlenhoff
  9. Lucia Banci  Is a corresponding author
  10. Roland Lill  Is a corresponding author
  1. Philipps-Universität, Germany
  2. University of Florence, Italy
  3. Philipps-Universität Marburg, Germany

Abstract

Assembly of mitochondrial iron-sulfur (Fe/S) proteins is a key process of cells, and defects cause many rare diseases. In the first phase of this pathway, ten Fe/S cluster (ISC) assembly components synthesize and insert [2Fe-2S] clusters. The second phase is dedicated to the assembly of [4Fe-4S] proteins, yet this part is poorly understood. Here, we characterize the BOLA family proteins Bol1 and Bol3 as specific mitochondrial ISC assembly factors that facilitate [4Fe-4S] cluster insertion into a subset of mitochondrial proteins such as lipoate synthase and succinate dehydrogenase. Bol1-Bol3 perform largely overlapping functions, yet cannot replace the ISC protein Nfu1 that also participates in this phase of Fe/S protein biogenesis. Bol1 and Bol3 form dimeric complexes with both monothiol glutaredoxin Grx5 and Nfu1. Complex formation differentially influences the stability of the Grx5-Bol-shared Fe/S clusters. Our findings provide the biochemical basis for explaining the pathological phenotypes of patients with mutations in BOLA3.

Article and author information

Author details

  1. Marta A Uzarska

    Institut für Zytobiologie und Zytopathologie, Philipps-Universität, Marburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  2. Veronica Nasta

    Magnetic Resonance Center CERM, University of Florence, Florence, Italy
    Competing interests
    The authors declare that no competing interests exist.
  3. Benjamin D Weiler

    Institut für Zytobiologie, Philipps-Universität Marburg, Marburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  4. Farah Spantgar

    Institut für Zytobiologie und Zytopathologie, Philipps-Universität, Marburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  5. Simone Ciofi-Baffoni

    Magnetic Resonance Center CERM, University of Florence, Florence, Italy
    Competing interests
    The authors declare that no competing interests exist.
  6. Maria Rosaria Saviello

    Magnetic Resonance Center CERM, University of Florence, Florence, Italy
    Competing interests
    The authors declare that no competing interests exist.
  7. Leonardo Gonnelli

    Magnetic Resonance Center CERM, University of Florence, Florence, Italy
    Competing interests
    The authors declare that no competing interests exist.
  8. Ulrich Mühlenhoff

    Institut für Zytobiologie und Zytopathologie, Philipps-Universität, Marburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  9. Lucia Banci

    Magnetic Resonance Center CERM, University of Florence, Florence, Italy
    For correspondence
    banci@cerm.unifi.it
    Competing interests
    The authors declare that no competing interests exist.
  10. Roland Lill

    Institut für Zytobiologie, Philipps-Universität Marburg, Marburg, Germany
    For correspondence
    lill@staff.uni-marburg.de
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8345-6518

Funding

Deutsche Forschungsgemeinschaft (SPP 1927)

  • Roland Lill

European Commission (iNEXT 653706)

  • Lucia Banci

Deutsche Forschungsgemeinschaft (SFB 987)

  • Ulrich Mühlenhoff
  • Roland Lill

European strategy forum on research infrastructures (Instruct)

  • Lucia Banci

LOEWE program of state Hesse, Germany (Synmikro)

  • Roland Lill

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2016, Uzarska et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,365
    views
  • 610
    downloads
  • 103
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Marta A Uzarska
  2. Veronica Nasta
  3. Benjamin D Weiler
  4. Farah Spantgar
  5. Simone Ciofi-Baffoni
  6. Maria Rosaria Saviello
  7. Leonardo Gonnelli
  8. Ulrich Mühlenhoff
  9. Lucia Banci
  10. Roland Lill
(2016)
Mitochondrial Bol1 and Bol3 function as assembly factors for specific iron-sulfur proteins
eLife 5:e16673.
https://doi.org/10.7554/eLife.16673

Share this article

https://doi.org/10.7554/eLife.16673

Further reading

    1. Biochemistry and Chemical Biology
    2. Computational and Systems Biology
    A Sofia F Oliveira, Fiona L Kearns ... Adrian J Mulholland
    Short Report

    The spike protein is essential to the SARS-CoV-2 virus life cycle, facilitating virus entry and mediating viral-host membrane fusion. The spike contains a fatty acid (FA) binding site between every two neighbouring receptor-binding domains. This site is coupled to key regions in the protein, but the impact of glycans on these allosteric effects has not been investigated. Using dynamical nonequilibrium molecular dynamics (D-NEMD) simulations, we explore the allosteric effects of the FA site in the fully glycosylated spike of the SARS-CoV-2 ancestral variant. Our results identify the allosteric networks connecting the FA site to functionally important regions in the protein, including the receptor-binding motif, an antigenic supersite in the N-terminal domain, the fusion peptide region, and another allosteric site known to bind heme and biliverdin. The networks identified here highlight the complexity of the allosteric modulation in this protein and reveal a striking and unexpected link between different allosteric sites. Comparison of the FA site connections from D-NEMD in the glycosylated and non-glycosylated spike revealed that glycans do not qualitatively change the internal allosteric pathways but can facilitate the transmission of the structural changes within and between subunits.

    1. Biochemistry and Chemical Biology
    2. Genetics and Genomics
    Conor J Howard, Nathan S Abell ... Nathan B Lubock
    Research Article

    Deep Mutational Scanning (DMS) is an emerging method to systematically test the functional consequences of thousands of sequence changes to a protein target in a single experiment. Because of its utility in interpreting both human variant effects and protein structure-function relationships, it holds substantial promise to improve drug discovery and clinical development. However, applications in this domain require improved experimental and analytical methods. To address this need, we report novel DMS methods to precisely and quantitatively interrogate disease-relevant mechanisms, protein-ligand interactions, and assess predicted response to drug treatment. Using these methods, we performed a DMS of the melanocortin-4 receptor (MC4R), a G-protein-coupled receptor (GPCR) implicated in obesity and an active target of drug development efforts. We assessed the effects of >6600 single amino acid substitutions on MC4R’s function across 18 distinct experimental conditions, resulting in >20 million unique measurements. From this, we identified variants that have unique effects on MC4R-mediated Gαs- and Gαq-signaling pathways, which could be used to design drugs that selectively bias MC4R’s activity. We also identified pathogenic variants that are likely amenable to a corrector therapy. Finally, we functionally characterized structural relationships that distinguish the binding of peptide versus small molecule ligands, which could guide compound optimization. Collectively, these results demonstrate that DMS is a powerful method to empower drug discovery and development.